PMC9779988_01
Patient reported outcomes for depression after Esketamine treatment. Over the course of treatment, the patient reported decreases in PHQ-9 and HAM-D scores. Series 1 indicates the PHQ-9 and series 2 indicates the HAM-D. Both demonstrate significant decreases in disease severity.
CRIPS2022-8992697.001.jpg
PMC9779988_01_CRIPS2022-8992697.001.jpg
fig1
From the start to the 46th session, the patient's PHQ-9 scores fell from 23 to 4 indicating a decline from severe to none-minimal (Figure 1).